News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
CAMBRIDGE, Mass., August 14, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 51,947 shares of its common stock to twelve newly hired employees, consisting of inducement stock options to purchase an aggregate …
Scholar Rock (NASDAQ: SRRK) announced that it granted inducement equity awards totaling 51,947 shares of common stock to twelve new employees. These awards, which include both stock options and restricted stock units, are part of the company's 2022 Inducement Equity Plan, designed to attract …
JP Morgan maintained an "Overweight" rating for Scholar Rock Holding Corp (SRRK) and raised its price target from $56.00 to $63.00, indicating a positive outlook. Despite this, the company has a low GF Score™ of 29/100 due to profitability and growth concerns, along with …
Invus Public Equities, L.P. and associated entities have reported an 8.0% beneficial ownership stake in Scholar Rock Holding Corporation (SRRK), totaling 9,575,013 shares of common stock. This is detailed in an amended Schedule 13G filing, which states that the shares were acquired for passive …
Scholar Rock Holding Corporation announced that the FDA review of its lead drug, apitegromab for spinal muscular atrophy, will proceed solely with its secondary fill-finish facility after an issue with its primary manufacturing site. Despite this change, the company confirmed that the Prescription Drug …
Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating for Scholar Rock Holding (SRRK) and maintained a $58.00 price target. Despite this, the company has a low GF Score™ of 29/100, indicating financial weaknesses, particularly in profitability and growth, and shows signs of potential …
Wedbush has reiterated an "Outperform" rating for Scholar Rock (SRRK) with a $58 price target, indicating a potential 12.45% upside. The company is near its 52-week high, and the analyst consensus remains "Buy" with an average target of $56.79. Institutional investors hold a significant …
HC Wainwright & Co. has reiterated its "Buy" rating for Scholar Rock Holding (SRRK), maintaining a price target of $65.00, suggesting a potential upside of 23% from its current price of $52.97. Despite this positive analyst outlook, the company has a low GF Score™ …
(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read …
This article provides a detailed overview of Scholar Rock Holding Corporation (SRRK), including its current stock price, financial data, and company profile. It highlights SRRK's focus on developing treatments for neuromuscular diseases and solid tumors, showcasing its key pipeline products and recent performance metrics …
Scholar Rock announced that the FDA review of its apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA) will proceed with a second fill-finish facility, following an Official Action Indicated (OAI) classification for their initial facility, Catalent Indiana. The company expects a potential …
Scholar Rock (NASDAQ:SRRK) reported quarterly earnings of ($0.84) per share, meeting analyst estimates, an improvement from ($0.98) per share a year ago. The company's U.S. approval for apitegromab is still targeted for September 30, despite delays in European approval due to FDA classification uncertainties …
Scholar Rock Holding Corp (SRRK) reported a consolidated net loss of $(215.4M) for the six months ended June 30, 2026, with a basic and diluted loss per share of $(1.67). The company recorded no product or commercial sales revenue during this period. Key business …
Scholar Rock reported better-than-expected Q2 2026 earnings per share and confirmed its lead drug apitegromab is on track for a U.S. regulatory decision by September 30, leading to a premarket stock increase. The company highlighted its readiness for launch with a second fill-finish facility …
Scholar Rock Holding Corporation has filed a prospectus supplement for a $200 million at-the-market (ATM) offering of common stock, replacing a previous offering. The biotech company, valued at $5.74 billion and up 38% in the past year, has already raised $257.7 million through its …
Scholar Rock (SRRK) reported Q2 2026 results, showing a net loss but significant progress on its apitegromab program for SMA. The company is pursuing a dual-track Biologics License Application strategy with two independent fill-finish facilities, aiming for FDA approval by September 2026 and preparing …
This article announces the filing of a Form 8K by Scholar Rock Holding Corp for August 6th. The brief piece includes the stock symbol SRRK and notes a significant price increase of 9.96%. The content primarily consists of market data and news headlines rather …
Scholar Rock announced its second-quarter 2026 financial results, highlighting ongoing FDA review for its Apitegromab Biologics License Application (BLA) for spinal muscular atrophy (SMA), with a potential approval by September 30, 2026. The company also initiated a Phase 2 trial for apitegromab in facioscapulohumeral …
This article provides a technical analysis of Scholar Rock Holding Corp (SRRK), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. As of the analysis, the stock's price momentum score is 4.07, and it is …
Scholar Rock (NASDAQ: SRRK) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. The presentation is scheduled for Wednesday, August 12, 2026, at 1:30 p.m. ET. A live webcast and replay of the event will be …
This article analyzes the financial health of Scholar Rock Holding Corp (SRRK), giving it a current financial score of 6.32, ranking 264 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable, but its operating efficiency is low. …
Kuehn Law, PLLC is investigating Scholar Rock Holding Corp (NASDAQ: SRRK) for potential breaches of fiduciary duties by its officers and directors, specifically concerning alleged self-dealing. The law firm is encouraging long-term SRRK shareholders to contact them to explore potential damages and corporate governance …
Search by ticker symbol or company name and select a result to open its chart.